Drug Safety Alert: IPC Flags ADR Linked To Vancomycin

New Delhi: The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of July, has revealed that Vancomycin, a tricyclic glycopeptide antibiotic, is linked with adverse drug reactions (ADRs) named Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome.

In connection with the above, the Indian Pharmacopoeia Commission (IPC) has cautioned healthcare professionals to diligently monitor the potential occurrence of adverse drug reactions (ADRs) when administering vancomycin.

This came after a preliminary analysis of adverse drug reactions (ADRs) from the Pharmacovigilance Programme of India (PVPI) database.

Vancomycin is a glycopeptide antibiotic used to treat severe but susceptible bacterial infections such as MRSA (methicillin-resistant Staphylococcus aureus) infections.

The alert noted that vancomycin is indicated for the treatment of serious infections due to Gram-positive cocci, including methicillin-resistant staphylococcal infections, brain abscesses, staphylococcal meningitis, and septicaemia.

Following the preliminary analysis of adverse drug reactions (ADRs) from the PVPI database, it is reported that vancomycin can lead to Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome.

The Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome presents clinically as an extensive mucocutaneous rash, accompanied by fever, lymphadenopathy, hepatitis, hematologic abnormalities with eosinophilia, and atypical lymphocytes.

In light of the above, the Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, has advised healthcare professionals, patients, and consumers to closely monitor the possibility of the above ADRs associated with the use of the above-suspected drugs.

Further, the safety alert added, “If such reaction is encountered, please report to the NCC-PVPI, IPC by filling out Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (http://www.ipc.gov.in), through Android Mobile App “ADR PvPI App” and PvP Helpline No. 1800-180-3024 (Toll-Free).”

Related Posts

Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

New Delhi — In a significant move to bring greater transparency and accountability in healthcare delivery, the Centre has directed all states and Union Territories to tighten regulatory oversight within…

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal, Ajinomoto team on ADC development and manufacturing

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Cancer cure must not be hostage to Big Pharma

Cancer cure must not be hostage to Big Pharma

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid